Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 1 Interventional

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

ClinicalTrials.gov ID: NCT06102902

Public ClinicalTrials.gov record NCT06102902. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encorafenib in treating patients with colorectal cancer that has not responded to previous treatment (refractory), that has come back after a period of improvement (relapsed), and that has spread from where it first started (primary site) to other places in the body (metastatic). ZEN003694 is a protein inhibitor that binds to BET proteins. When ZEN003694 binds to BET proteins, it disrupts gene expression. Preventing the expression of certain growth-promoting genes may inhibit proliferation of tumor cells that over-express BET proteins. Immunotherapy with monoclonal antibodies, such as cetuximab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Encorafenib is an enzyme inhibitor. It inhibits pathways that are responsible for controlling cell proliferation and survival, which may lead to a decrease in tumor cell proliferation. Both cetuximab and encorafenib have been approved to treat cancer. Adding ZEN003694 to cetuximab and encorafenib may be more effective at treating patients with refractory metastatic colorectal cancer than giving the usual treatment (cetuximab and encorafenib) alone.

Study identification

NCT ID
NCT06102902
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Enrollment
30 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 5, 2024 (Actual)
Primary completion
Jan 30, 2027 (Estimated)
Completion
Jan 30, 2027 (Estimated)
Last update posted
Sep 23, 2026

2024 – 2027

United States locations

U.S. sites
16
U.S. states
8
U.S. cities
15
Facility City State ZIP Site status
UC Irvine Health Cancer Center-Newport Costa Mesa California 92627 Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine California 92612 Recruiting
Los Angeles General Medical Center Los Angeles California 90033 Suspended
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868 Recruiting
UCHealth University of Colorado Hospital Aurora Colorado 80045 Recruiting
University of Kansas Clinical Research Center Fairway Kansas 66205 Active, not recruiting
University of Kansas Cancer Center Kansas City Kansas 66160 Active, not recruiting
University of Kansas Hospital-Indian Creek Campus Overland Park Kansas 66211 Active, not recruiting
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205 Active, not recruiting
Ochsner Medical Center Jefferson New Orleans Louisiana 70121 Active, not recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 Recruiting
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 Recruiting
UT MD Anderson Cancer Center Houston Texas 77030 Recruiting
University of Virginia Cancer Center Charlottesville Virginia 22908 Recruiting
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06102902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2026 · Synced Oct 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06102902 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →